NeuroPace Inc (NeuroPace) is a commercial-stage medical device company that focuses on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its major product includes RNS System, is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes an RNS neurostimulator, cortical strip leads and depth leads and a Patient Remote Monitor, as well as other implantable and non-implantable accessories. NeuroPace is headquartered in Mountain View, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company NeuroPace Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
NeuroPace Inc Company Overview
NeuroPace Inc Company Snapshot
NeuroPace Inc Pipeline Products and Ongoing Clinical Trials Overview
NeuroPace Inc – Pipeline Analysis Overview
NeuroPace Inc - Key Facts
NeuroPace Inc - Major Products and Services
NeuroPace Inc Pipeline Products by Development Stage
NeuroPace Inc Ongoing Clinical Trials by Trial Status
NeuroPace Inc Pipeline Products Overview
NeuroPace RNS System - Adolescents
NeuroPace RNS System - Adolescents Product Overview
NeuroPace RNS System - Idiopathic Generalized Epilepsy
NeuroPace RNS System - Idiopathic Generalized Epilepsy Product Overview
NeuroPace RNS System - Idiopathic Generalized Epilepsy Clinical Trial
NeuroPace RNS System - Lennox Gastaut Syndrome
NeuroPace RNS System - Lennox Gastaut Syndrome Product Overview
NeuroPace Inc - Key Competitors
NeuroPace Inc - Key Employees
NeuroPace Inc - Locations And Subsidiaries
Head Office
Recent Developments
NeuroPace Inc, Recent Developments
Mar 05, 2024: NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
Dec 21, 2023: NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
Dec 04, 2023: NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
Oct 17, 2023: NeuroPace Announces RNS System Enhancements Designed to Streamline Care
Jan 09, 2023: NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors
Nov 30, 2022: NeuroPace feasibility study of Its RNS system for Lennox-Gastaut Syndrome now underway
Oct 12, 2022: First patient implanted in NeuroPace’s RNS System trial for IGE
Oct 11, 2022: NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)
Aug 23, 2022: NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference